
FDA has approved another treatment for patients with peripheral T-cell lymphoma (PTCL), a rare yet aggressive type of non-Hodgkin lymphoma. Belinostat (Beleodaq) by Spectrum Pharmaceuticals was approved under FDA’s accelerated approval program. It is indicated for patients with relapsed or refractory PTCL.